Exploring the Role of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in the Management of Cardiogenic Shock: Pathophysiological Insights and Therapeutic Potential
Main Article Content
Abstract
Cardiogenic shock remains a critical condition characterized by profound myocardial dysfunction leading to end-organ hypoperfusion and high mortality rates despite advances in supportive therapies. While traditional management focuses on inotropes, vasopressors, and mechanical circulatory support, recent evidence suggests that metabolic modulation could provide additional benefits. Dipeptidyl peptidase-4 (DPP-4) inhibitors, primarily used in type 2 diabetes mellitus, have demonstrated cardioprotective effects through pleiotropic mechanisms, including anti-inflammatory, endothelial-protective, and metabolic-modulating actions. This review examines the potential utility of DPP-4 inhibitors in the context of cardiogenic shock, emphasizing their mechanisms of action, experimental and clinical data, and the feasibility of integrating these agents into the current therapeutic paradigm. We highlight gaps in knowledge and propose directions for future research to determine the clinical efficacy of DPP-4 inhibitors in this high-risk population.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413–420. doi: 10.7326/0003-4819-141-6-200409210-00006.
II. .Mannucci E, Dicembrini I, Lauria A, Pozzilli P. Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care. 2013;36(Suppl 2):S259–S263. doi: 10.2337/dcS13-2018.
III. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011; 343:d4169. doi: 10.1136/bmj.d4169.
IV. .Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, Underwood P, Park KH, Seufert J, Kang ES, et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism. 2018;78:13–42. doi: 10.1016/j.metabol.2017.08.010.
V. Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol. 2015;14:129. doi: 10.1186/s12933-015-0294-0.
VI. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865.
VII. Chin HJ, Nam JH, Lee EK, Shin JY. Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: a retrospective cohort study. Medicine (Baltimore) 2017;96(25):e7213.
doi: 10.1097/MD.0000000000007213.
VIII. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
doi: 10.1056/NEJMoa1603827.
IX. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094.
doi: 10.1056/NEJMc1600827.
X. Lehrke M, Leiter LA, Hehnke U, Thiemann S, Bhandari A, Meinicke T, Johansen OE. Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials. J Diabetes Complications. 2016;30(7):1378–1384. doi: 10.1016/j.jdiacomp.2016.06.015.
XI. Aroor AR, Sowers JR, Jia G, DeMarco VG. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol. 2014;15:H477–H492. doi: 10.1152/ajpheart.00209.2014.
XII. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849–870.
doi: 10.1161/CIRCULATIONAHA.117.028136.
XIII. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116(8):1491–1504.
doi: 10.1161/CIRCRESAHA.116.305665.
XIV. 14.Duan L, Rao X, Xia C, Rajagopalan S, Zhong J. The regulatory role of DPP4 in atherosclerotic disease. Cardiovasc Diabetol. 2017;16(1):76.
doi: 10.1186/s12933-017-0558-y.
XV. Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta D, Kusaka H, Ma M, Nakagawa T, Lin B, et al. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol. 2014;13:157. doi: 10.1186/s12933-014-0157-0.
XVI. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586. doi: 10.1001/jama.294.20.joc50147.
XVII. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
doi: 10.1056/NEJMoa072761.